Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-APlus adjuvant dabrafenib + trametinib pyrexia management study
2018-000168-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma and cutaneous melanoma (CM), sponsored by Novartis. Started Jun 2018; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on 2018-000168-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000168-27.